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Myelodysplastic syndromes (MDS) are age-dependent stem cell malignancies that share biological features 
of activated adaptive immune response and ineffective hematopoiesis. Here we report that myeloid-derived 
suppressor cells (MDSC), which are classically linked to immunosuppression, inflammation, and cancer, were 
markedly expanded in the bone marrow of MDS patients and played a pathogenetic role in the development 
of ineffective hematopoiesis. These clonally distinct MDSC overproduce hematopoietic suppressive cytokines 
and function as potent apoptotic effectors targeting autologous hematopoietic progenitors. Using multiple 
transfected cell models, we found that MDSC expansion is driven by the interaction of the proinflammatory 
molecule S100A9 with CD33. These 2 proteins formed a functional ligand/receptor pair that recruited compo-
nents to CD33’s immunoreceptor tyrosine-based inhibition motif (ITIM), inducing secretion of the suppres-
sive cytokines IL-10 and TGF-β by immature myeloid cells. S100A9 transgenic mice displayed bone marrow 
accumulation of MDSC accompanied by development of progressive multilineage cytopenias and cytological 
dysplasia. Importantly, early forced maturation of MDSC by either all-trans-retinoic acid treatment or active 
immunoreceptor tyrosine-based activation motif–bearing (ITAM-bearing) adapter protein (DAP12) interrup-
tion of CD33 signaling rescued the hematologic phenotype. These findings indicate that primary bone mar-
row expansion of MDSC driven by the S100A9/CD33 pathway perturbs hematopoiesis and contributes to the 
development of MDS.
Introduction
Understanding the selective pressures and mechanisms involved in 
the initiation of stem cell malignancies is critical to development 
of effective strategies for prevention and treatment. Inflammatory 
molecules have long been implicated as regulatory cues driving the 
proliferation and apoptotic death of hematopoietic progenitors in 
myelodysplastic syndromes (MDS) (1–3). Chronic immune stimu-
lation, coupled with senescence dependent changes in both hema-
topoietic stem/progenitor cells (HSPC) and the BM microenviron-
ment, are believed to be critical to the pathogenesis of the disease 
(4). Increasing evidence implicates the activation of innate immune 
signaling in both hematopoietic senescence and the pathobiology 
of MDS (5). TLR4, for instance, is overexpressed in MDS BM HSPC 
and is implicated in progenitor apoptosis and subsequent develop-
ment of cytopenias (6). Furthermore, gene expression of the TLR 
adaptor E3 ubiquitin ligase, TNF receptor-associated factor-6 
(TRAF6), is markedly upregulated in MDS CD34+ cells (7) accom-
panied in some cases by amplification of genomic regions encod-
ing TRAF6 or the Toll IL-1 receptor domain-containing adap-
tor protein (TIRAP), key intermediates in TLR4 signaling (8, 9). 
Recent investigations showed that TLR signaling is constitu-
tively activated in MDS with chromosome 5q deletion [del(5q)] 
as a result of allelic deletion of microRNA 145 (miRNA-145) and 
miRNA-146a and consequent upregulation of their respective 
targets, TIRAP and TRAF6 (10). Moreover, knockdown of these 
specific miRNAs or overexpression of Traf6 in murine HSPC reca-
pitulates the hematologic features of del(5q) MDS in a transplant 
model (10), providing convincing evidence that sustained TLR 
activation is a critical factor driving the malignant phenotype. 
More recent findings indicate that TRAF6 is essential for survival 
and proliferation of MDS HSPC (11) and sustained TLR activa-
tion skews their commitment toward the myeloid lineage while 
suppressing osteoblast differentiation (12, 13), analogous to the 
senescence-dependent changes observed with normal aging (14).
Immature myeloid-derived suppressor cells (MDSC), known to 
accumulate in tumor-bearing mice and cancer patients, are site-
specific inflammatory and T cell immunosuppressive effector 
cells that contribute to cancer progression (15, 16). Their suppres-
sive activity is in part driven by inflammation-associated signal-
ing molecules, such as the danger-associated molecular pattern 
(DAMP) heterodimer S100A8/S100A9 (also known as myeloid-
related protein 8 [MRP-8] and MRP-14, respectively), which inter-
act with several innate immune receptors that are involved in the 
biology of MDSC activation (17–20). Murine CD11b+Gr1+ MDSC 
form the basis of the vast majority of the mechanistic studies; how-
ever, much less has been reported on their human counterparts. 
Human MDSC lack most markers of mature immune cells (LIN–, 
HLA-DR–) but possess CD33, the prototypical member of sialic 
acid–binding Ig-like super-family of lectins (Siglec) (15, 21–23). 
Importantly, while its precise action is unknown, CD33 possesses 
an immunoreceptor tyrosine-based inhibition motif (ITIM) that is 
associated with immune suppression (23).
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Here, we show that LIN–HLA-DR–CD33+ MDSC specifically 
accumulate in the BM of MDS patients (herein referred to as 
MDS-MDSC) and impair hematopoiesis through a mechanism 
that involves S100A9 as an endogenous ligand for CD33-initiated 
signaling. Importantly, using S100A9 transgenic (S100A9Tg) mice, 
we show that sustained activation of this inflammatory pathway 
leads to the development of MDS and that this hematologic phe-
notype is rescued by strategies that suppress CD33 ITIM signaling. 
Our finding that S100A9 ligates CD33 to induce MDSC expan-
sion suggests that targeting this pathway may provide a therapeu-
tic approach for the treatment of MDS. Finally, the discovery of 
this signaling pathway verifies the role of S100A9 as an important 
initiator of immune suppression. S100A9Tg mice may therefore 
serve as a useful model for the study of MDS pathogenesis, treat-
ment, and the overall role of MDSC in cancer.
Results
Lin–HLA-DR–CD33+ MDSC are expanded in MDS primary BM speci-
mens and direct the suppression of autologous erythroid precursors. BM 
mononuclear cells (BM-MNC) were isolated from MDS BM aspi-
rates (n = 12), age-matched healthy BM (n = 8), or non-MDS cancer 
patients (4 breast and 4 lymphoma) and analyzed for the presence 
of LIN–HLA-DR–CD33+ MDSC by flow cytometry. MDS patients 
exhibited markedly higher numbers of MDSC (median 35.5%, 
P < 0.0001) compared with healthy donors or non-MDS cancer 
patients (less than 5%, Figure 1A). To determine whether MDS-
MDSC are derived from the malignant MDS clone, LIN–HLA-DR–
CD33+ MDSC were sorted from MDS specimens with chromo-
some 5q [del(5q)] or 7q [del(7q)] deletion and analyzed by FISH 
with specific probes. Cytogenetically abnormal cells harboring 
del(5q) or del(7q) were restricted to the non-MDSC population, 
whereas LIN–HLA-DR–CD33+ MDSC displayed a correspondingly 
normal chromosome complement (Figure 1B). Exome sequenc-
ing studies have shown that clonal somatic gene mutations are 
demonstrable in the vast majority of MDS specimens lacking chro-
mosome abnormalities by metaphase karyotyping. To further eval-
uate the relationship between MDS-MDSC and the MDS clone, we 
performed a quantitative PCR (qPCR) array of the most common 
gene mutations in MDS (QIAGEN) in purified MDS-MDSC and 
non-MDSC populations from primary BM MDS specimens. Muta-
tions involving CBL, EZH2, IDH1/2, N-RAS, SRSF2, U2A535, and 
RUNX1 genes were detected in the MDS specimens; however, all 
mutations were restricted to the MDSC-depleted fraction (Supple-
mental Table 1; supplemental material available online with this 
article; doi:10.1172/JCI67580DS1), indicating that LIN–HLA-DR– 
CD33+ MDSC are distinct from the malignant clone.
Recognized functional properties of MDSC include suppres-
sion of antigen-stimulated or CD3-stimulated T cell proliferation 
and IFN-γ production (15, 24). T cells purified from the BM of 
MDS patients showed reduced T cell proliferation (Figure 1C) and 
IFN-γ production (Figure 1D) after coculture with autologous 
MDS-MDSC, demonstrating the expected suppressive activity of 
these cells. To further validate these findings, we depleted MDSC 
from MDS BM specimens prior to anti-CD3/anti-CD28 stimula-
tion and then added the MDSC back to the control group. MDSC 
depletion significantly improved T cell responses compared with 
the MDSC-supplemented group (Figure 1E), thereby linking the 
observed impaired T cell responsiveness to the actions of BM-
derived MDSC. In addition, suppressive MDS-MDSC overpro-
duced suppressive cytokines such as IL-10 and TGF-β (Figure 1, 
F and G) as well as nitric oxide (NO) and arginase compared with 
LIN–HLA-DR–CD33+ cells isolated from healthy donors (Figure 1, 
H and I). Collectively, these data demonstrate that LIN–HLA-DR–
CD33+ MDSC are a unique and functional cellular subset support-
ing a proinflammatory microenvironment and immune tolerance 
in the BM of MDS patients.
MDSC-mediated suppressive and cytotoxic effector functions 
require direct contact with target cells. One mechanism utilized 
by cytotoxic effectors is the mobilization of pore-forming gran-
ules and the release of caspase-activating effector proteases, such 
as granzyme B, to the site of effector/target contact, which induces 
apoptosis of the target cell (25). Since MDSC reside in close prox-
imity with hematopoietic progenitor cells (HPC), which in MDS 
display an increased apoptotic rate, we tested whether MDSC-
mediated cytostatic activity may contribute to HPC death. To 
address this, we examined MDS-MDSC granule mobilization and 
release of granzyme B using 4-color immunofluorescence staining. 
MDS-MDSC exhibited strong granzyme B polarization at the site 
of cell contact with CD235a+ (glycophorin A)/CD71+ autologous 
erythroid precursors (Figure 1J). After 30 minutes incubation, the 
frequency of such effector/target conjugates in MDS patient speci-
mens was significantly higher (34%) than in samples from healthy 
donors (5% P < 0.001, Figure 1, K and L). These cellular interactions 
resulted in apoptosis of targeted erythroid precursors (Figure 1M), 
demonstrating that in addition to known MDSC-mediated 
immune suppressive functions, there is an unrecognized MDSC-
mediated hematopoietic suppressive capacity. To corroborate this 
finding, we examined the effects of MDSC on the proliferative 
capacity of HSPC in MDS-MDSC–depleted, HSPC-enriched BM 
patient specimens in a methylcellulose colony formation assay. 
Burst-forming unit–erythroid (BFU-E) and GM-CFU colony for-
mation were significantly higher in MDSC-depleted specimens 
compared with both MDSC-supplemented and unsorted samples 
(Figure 1N), demonstrating that MDSC have a direct suppressive 
role on erythroid and myeloid progenitor cell development.
Figure 1
Increased accumulation and function of MDSC in BM of MDS patients. 
(A) Percentage of MDSC in the BM-MNC of MDS (n = 12), age-
matched healthy (n = 8), and non-MDS cancer specimens (n = 8, 
P < 0.0001). (B) Chromosome 7 FISH of sorted MDSC or non-MDSC 
from MDS BM-MNC (n = 5, CEP7 is green and 7q31 orange). 3H-thy-
midine incorporation (C) and IFN-γ ELISA (D) of stimulated autologous 
T cells cocultured with sorted MDS-MDSC at 1:0.25 and 1:0.5 ratios 
(T cells:MDSC). Error bars denote SD of 3 separate patient samples 
tested in triplicate. (E) BrdU incorporation of stimulated T cells after 
admixing with autologous unsorted, MDSC depleted (–MDSC), or 
remixed (+MDSC) BM-MNC. Sorted MDSC from MDS or healthy donor 
BM tested for IL-10 (F), TGF-β (G), NO (H), and arginase (I) produc-
tion after 24 hours of culture. (J) MDSC/erythroid precursor contact 
zone of admixed sorted MDS-MDSC and autologous erythroid precur-
sors at a ratio of 1:3 (MDSC/erythroid precursor) by microscopy at 0 
and 30 minutes. Cells were stained for CD71 (pink), CD235a (blue), 
CD33 (red), and granzyme B (green). (K) Sorted MDSC from MDS or 
healthy donors labeled with CD33 (red) and granzyme B (green) coin-
cubated with purified autologous erythroid precursors (0 or 30 minutes) 
and monitored by microscopy. (L) Counts of MDSC-HPC conjugate 
mobilized granules. Original magnification, ×400 (B); ×600 (J and K). 
(M) Annexin V exposure on erythroid precursors (CD71+CD235a+) incu-
bated with or without sorted autologous MDS-MDSC. (N) Colony-form-
ing ability of unsorted, –MDSC, or remixed (+MDSC) MDS BM-MNC 
(ratio of 1:3). *P < 0.005; **P < 0.001; ***P < 0.05.
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Increased CD33 expression and signaling contribute to MDSC sup-
pressive functions and hematopoietic impairment. MDSC in humans 
characteristically express the surface transmembrane glycopro-
tein CD33, a Siglec 3 receptor that along with other members 
of this family, has prominent roles in inflammation (23, 26–35). 
However, the involvement of CD33 in myelopoiesis remains 
unexplored. Hence, we investigated the relationship between 
CD33 membrane expression density on MDS-MDSC and its 
activation and maintenance in MDS BM. We found that these 
cells robustly express CD33 at levels higher than LIN–HLA-DR–
CD33+ cells isolated from non–MDS-associated cancer patients 
and healthy donor BM cells (Figure 2A). To explore the func-
tional consequences of CD33 engagement, we crosslinked CD33 
in U937 cells (a human monocytic cell line with high CD33 
expression), which triggered IL-10, TGF-β, and VEGF secretion 
(Figure 2B). To examine whether CD33 can promote MDSC 
accumulation and/or activation, we overexpressed CD33 with 
an adenovirus vector in BM-MNC from healthy donors, which 
Figure 2
CD33 signals to enhance MDSC suppressive functions. (A) BM-MNC from MDS patients (n = 12), age-matched healthy donors (n = 8), and 
non-MDS cancers (n = 8) were analyzed for CD33’s MFI. *P < 0.0005. (B) Concentration of IL-10, TGF-β, and VEGF from the supernatant of 
CD33 (or isotype) crosslinked U937 cells. Bars represent mean ± SEM of 3 wells on 3 separate experiments. (C) BM-MNC were isolated from 
healthy donors and infected with an adenoviral vector containing either GFP (Ad-GFP) or CD33 (Ad-CD33) for 72 hours before flow cytometric 
analysis of the mature myeloid markers, CD11c, CD80, and CCR7, with noninfected cells as a control (data not shown). (D) BFU and (E) CFU 
colony-forming assay. After sorting out MDSC from the BM of MDS patients, the remaining MDSC-negative cells were cultured with MDSC that 
had been mock infected or infected with LV containing nontargeted shRNA or CD33 shRNA (shCD33) for 14 days. The colony formation assay 
was performed. The MDSC were also cultured for 72 hours after infection with LV containing constructs described above before culturing with 
MDSC-negative BM cells. *P < 0.001, versus cells treated with control shRNA. The supernatants were collected and assayed for IL-10 (F) and 
TGF-β (G) by ELISA. *P < 0.05, versus cells treated with control shRNA. (H) The shCD33-treated cells were also analyzed for arginase activity. 
*P < 0.05, versus cells treated with control shRNA.
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significantly suppressed myeloid cell development, as evidenced 
by reduced expression of the maturation markers CD11c, CD80, 
and CCR7 (Figure 2C). To further establish the role of CD33 in 
MDSC-mediated BM suppression, we knocked down CD33 in 
MDS-MDSC using a lentiviral vector (LV) containing CD33-
specific shRNA. Coculture of autologous HSPC with CD33 
shRNA–treated MDS-MDSC resulted in a 2- to 3-fold increase in 
BFU-E and GM-CFU colony recovery compared with those cul-
tured with scrambled shRNA-treated and nontransduced MDS-
MDSC and healthy donor BM MDSC (Figure 2, D and E). More-
over, production of IL-10, TGF-β, and arginase was reduced in 
CD33 shRNA–treated MDS-MDSC compared with control cells 
(Figure 2, F–H). Collectively, these data delineate a role for CD33 
in MDSC activation and expansion in MDS and directing hema-
topoietic impairment.
S100A9 is a native ligand for CD33. Although our investigations 
show that CD33/Siglec 3 is a key receptor involved in functional 
activation of MDSC, its native ligand remains unknown. There-
fore, we attempted to identify potential ligand(s) for this recep-
tor by creating a chimeric fusion protein with the ectodomain of 
CD33 and the Fc portion of human IgG (hereafter referred to as 
CD33-fusion). BM cell lysates from MDS patients were immuno-
precipitated with the CD33-fusion followed by high-throughput 
mass-spectrometric analysis on associated peptides. S100A9, an 
inflammatory signaling molecule known to activate MDSC, was 
among the most prominent protein bands identified (Figure 3A). 
To confirm the specificity of the binding of this DAMP to CD33, 
we prepared both S100A8 and S100A9 transfectants in the rhab-
domyosarcoma cell line SJCRH30, which lacks detectable expres-
sion of endogenous CD33 or S100A9. The CD33-fusion (APC) 
stained only S100A9 transfected cells, but not S100A8 transfect-
ed cells, confirming binding specificity (Figure 3B; transfectants 
were stained with FITC, and specific binding by the CD33-fusion 
was stained with APC, shown in red; nuclei were stained with 
DAPI). Direct binding of S100A9 to CD33 was confirmed further 
in a sandwich ELISA where the capture antibody was anti-S100A9 
(Figure 3C) as well as by dot blot analysis of transfected cell lysates 
with CD33-fusion (Figure 3D), demonstrating the specificity of 
the interaction. To fully corroborate the binding of this pair, we 
set out to perform a reverse immunoprecipitation on CD33 trans-
fected cells showing that S100A9 coprecipitated with CD33 only 
in recombinant human S100A9–treated (rhS100A9-treated) cells 
(Figure 3E). To validate clinically the ligand specificity in MDS 
patients, we compared the pull-down with CD33-fusion from 
PBMC and BM from healthy as well as MDS patients’ samples. As 
expected, the highest amount of S100A9 was precipitated from 
the BM of MDS patient specimens (Figure 3F). Next, to under-
stand the kinetics of S100A9 and CD33 interactions, SJCRH30 
cells were transfected with either vector or CD33 and incubated 
with rhS100A9 tagged with DDK (DYKDDDDK epitope, same 
epitope as Flag). We observed a time-dependent increase in bind-
ing of rhS100A9 to stable SJCRH30-CD33 cells but no binding 
to vector transfected cells (Figure 3G). To demonstrate the func-
tionality of this ligation pair, we added rhS100A9 to SJCRH30-
CD33 cells, which triggered CD33-mediated upregulation of 
IL-10 and TGF-β expression (Figure 3, H and I). To confirm that 
rhS100A9 can recapitulate our observation of the secretion of 
these cytokines after crosslinking CD33, we repeated the experi-
ments in U937 cells with rhS100A9 and again found an increase 
in production of both cytokines (Figure 3, J and K). Importantly, 
BM plasma concentration of S100A9 was significantly increased 
in MDS patients compared with BM plasma from healthy donors 
(Figure 3L). Moreover, the engagement of CD33 with rhS100A9 
in MDS-MDSC from patient BM resulted in a time-dependent 
colocalization of this ligand/receptor pair (Figure 3M). It is 
well recognized that CD33 signals through phosphorylation of 
ITIMs that recruit Src homology region 2 domain-containing 
phosphatase-1 (SHP-1) (31). rhS100A9 ligation correspondingly 
increased the recruitment of SHP-1, confirming that CD33 signals 
through its ITIM after S100A9 ligation in MDS BM (Figure 3N). 
In addition, directly treating CD33-transfected SJCRH30 with the 
BM plasma of MDS patients triggered the recruitment of SHP-1 
to ITIM when compared with cells treated with the plasma of 
healthy donors, suggesting that increased secretion of S100A9 in 
the local BM microenvironment may have a role in the activation 
of CD33-ITIM signaling (Figure 3O).
S100A8/S100A9 engagement of CD33 triggers MDS-MDSC acti-
vation. Having established S100A9 and CD33 as a functional 
ligand/receptor pair, we explored the role of this interaction 
in replicating the functional responses observed with receptor 
crosslinking. We again induced CD33 overexpression in healthy 
BM cells through adenovirus transfection and studied their 
immunosuppressive properties with or without the addition of 
rhS100A9. Forced expression of CD33 induced a parallel increase 
in gene expression and secretion of the suppressive cytokines 
IL-10 and TGF-β (Figure 4, A–D), which was greatly increased by 
the addition of rhS100A9. Secretion of the suppressive cytokine 
TGF-β was only observed after rhS100A9 treatment of CD33 
transfected cells (Figure 4D), accompanied by an increase in the 
expression of NOS2 and ARG2, consistent with the suppressive 
cytokine profile (Figure 4, E and F). Figure 4, G and H, demon-
strates the transfection efficiency of the CD33 adenovirus at 
both the gene and protein expression levels measured by qPCR 
and GFP by flow cytometry, respectively.
To further delineate the specific role of S100A9’s ligation with 
CD33 compared with its other ligands, we blocked RAGE, TLR4, 
and CD33 as well as their combination with antibodies before 
treating healthy BM cells with rhS100A9. As expected, rhS100A9 
treatment is able to induce the generation of suppressive cytokines 
as compared with untreated cells. Importantly, our data show 
that blockade of CD33 reduced both IL-10 and TGF-β production 
(Figure 4, I and J), while treatment with anti-RAGE and anti-TLR4 
had no significant effects on IL-10 production but displayed mod-
est suppression of TGF-β secretion and expression (Figure 4, I and J). 
These findings suggest that although CD33 plays a critical role in 
the secretion of both cytokines, we cannot completely exclude the 
contribution of other receptors associated with local BM inflamma-
tion. To confirm that S100A9 expression contributes to inflamma-
tion in the BM microenvironment, we knocked down S100A8 and 
S100A9 in MDS-MDSC using gene-specific shRNAs (Figure 4K). 
Given that S100A9 usually pairs with S100A8 as a heterodimer 
and both are concomitantly regulated, we were not surprised 
to find reciprocal changes in gene expression after downregula-
tion in the expression of the alternate protein (36). Importantly, 
reduction of S100A8/S100A9 expression profoundly attenuated 
IL-10 and TGF-β production (Figure 4, L and M) and rescued 
autologous BFU-E and GM-CFU colony formation (Figure 4N). 
These data show that inflammation-associated S100A8/S100A9 
signaling plays a critical role in the activation of MDS-MDSC and 
suppresses normal hematopoiesis.
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S100A9Tg mice recapitulate features of human MDS. Given our find-
ings that S100A9 triggers CD33/Siglec 3 signaling and is involved 
in MDSC activation (17, 18, 37), we generated S100A9Tg mice 
to study MDSC-associated inflammation (37). Since MDS is an 
age-associated disease, we began by analyzing changes in the pro-
portion of BM Gr1+CD11b+ cells (cells with MDSC-phenotype, 
hereafter also referred to as MDSC) with age in S100A9Tg com-
pared with S100A9 knockout (S100A9KO) (38) or WT mice at 
6, 18, or 24 weeks of age. We observed a marked age-dependent 
accumulation of MDSC in the BM of S100A9Tg mice, but not in 
S100A9KO or WT mice, that reached its maximum by 18 weeks 
and was maintained into 24 weeks of age (Figure 5A). Similarly, 
the proportion of MDSC in PBMC and spleen also increased with 
age (Figure 5B). Although changes in the proportion of MDSC in 
the spleen were comparatively less than in the BM, it was accom-
panied by a decrease in the proportion of mature cells (Figure 5, 
C and D), effectively increasing the ratio of immature to mature 
cells in this hematopoietic organ. Functionally, only the MDSC 
from 24-week-old S100A9Tg mice, but not S100A9KO or WT 
mice, significantly inhibited BFU-E (Figure 5E) and GM-CFU 
formation (data not shown), which was rescued after depletion of 
MDSC in the S100A9Tg group (Figure 5E). Importantly, as further 
evidence of the role of S100A9 as an essential inflammatory factor 
regulating MDSC expansion and suppressive activity, IL-10 and 
TGF-β secretion were significantly increased in S100A9Tg mice 
compared with KO or WT animals (Figure 5F).
To evaluate the in vivo consequences of S100A9 overexpression 
on hematopoiesis, serial complete blood counts (CBC) were ana-
lyzed from WT and S100A9Tg mice at 6, 18, and 24 weeks of age. 
S100A9Tg mice developed progressive multilineage cytopenias 
characterized by decreasing hemoglobin (Hgb), rbc number, neu-
trophil and platelet counts evident as early as 6 weeks of age. By 
18 weeks, S100A9Tg mice exhibited severe anemia and thrombo-
cytopenia with a greater than 22.0% decrease in rbc, 20.1% decrease 
in Hgb, and 77.8% decrease in platelets (Table 1). By 24 weeks of 
age, S100A9Tg mice developed severe pancytopenia. Histological 
examination of BM aspirates and biopsy sections from WT mice 
displayed normal morphology and cytological features (Figure 5, 
G–J). In contrast, the BM of S100A9Tg mice was hypercellular 
(95% cellularity), accompanied by tri-lineage cytological dysplasia 
(Figure 5, K–N). Megakaryocyte morphology recapitulated the dys-
plastic features characteristic of human MDS, with a preponder-
ance of mononuclear or hypolobated forms. Erythroid precursors 
displayed megaloblastoid maturation with abnormal hemoglobi-
nation and occasional binucleation. Nuclear budding and bizarre 
mitotic forms were also apparent (Figure 5, K–N). The percent-
age of myeloid lineage cells identified by myeloperoxidase stain-
ing increased significantly in S100A9Tg mice, reaching a mean of 
62.5% ± 5.6% vs. 35% ± 10% in WT mice (P = 0.0099). Assessment 
of distribution of cycling cells by Ki67 staining showed a marked 
increase in the proportion of Ki67+ cells in the endosteal region of 
S100A9Tg mice compared with WT mice (mean, 78.5% ± 6.1% vs. 
37.5% ± 3.7%; P = 0.0013), whereas there was no discernible differ-
ence in the central marrow region (mean Tg, 9.75 ± 0.77 vs. WT, 
10 ± 2.04; P = 0.62, Supplemental Figure 1).
Although this model closely replicates the inflammatory milieu 
observed in human MDS, HSPC from S100A9Tg mice also express 
the S100A9 protein. Given that the provenance of this protein in 
human MDS is unknown, we investigated cellular expression of 
S100A9 in MDS BM-MNC by flow cytometry. S100A9 intracellular 
staining was detected in CD33+ cells, whereas CD34+ HSPC had 
no demonstrable S100A9 expression (Figure 5, O and P). We did 
not detect S100A9 expression in other immune cells, such as CD3+ 
lymphocytes, CD19+ B cells, or CD56+ NK cells (data not shown).
Analysis of the role of MDSC by adoptive transfer of enriched HSPC 
from S100A9Tg mice. To more accurately delineate the role of 
MDSC from S100A9Tg mice in hematopoiesis, we performed 
competitive adoptive transfer of enriched HSPC into lethally 
irradiated (900 cGy) female FVB/NJ mice with age-matched WT 
HSPC, S100A9Tg HSPC, or an admixture (1:1 ratio) of enriched 
BM HSPC from male mice. When we used a male-to-female SRY 
gene expression PCR approach to monitor engraftment (39, 40), 
all mice experienced around 90% engraftment (Supplemental 
Figure 2). After engraftment (defined as wbc > 3 × 103 cells/μl 
in WT recipients at 8 weeks), recipients of WT HSPC had pro-
portions of both BM-derived Gr1+CD11b+ and KLS stem cells 
(Figure 6, A and C) that were comparable to levels in untrans-
planted WT mice (Figure 5A). In contrast, adoptive transfer 
with S100A9Tg enriched HSPC generated a high proportion 
of GFP-expressing Gr1+CD11b+ MDSC (Figure 6B) accompa-
nied by a reduced proportion of HSPC, findings analogous to 
our observations in older transgenic mice (Figure 6C). However, 
mice that received the admixed HSPC population had a propor-
tion of MDSC approaching that in WT adoptively transferred 
mice (∼30%). Notably, nearly 50% of MDSC lacked GFP expres-
sion, indicating origination from WT HSPC (Figure 6B), whereas 
the remaining GFP+ MDSC derived from S100A9Tg donor cells. 
Although the total MDSC population did not increase to the 
level observed in the S100A9Tg adoptively transferred mice, 
we observed a decreased proportion of HSPC to levels found in 
mice transplanted with S100A9Tg donor cells (Figure 6C). These 
findings indicate that the smaller population of activated MDSC 
from S100A9Tg donor cells had sufficient suppressive activity to 
Figure 3
Identification of S100A9 as a native ligand for CD33. (A) Coomassie 
blue staining of BM lysates precipitated with either control IgG or CD33-
fusion. (B) Transfected SJCRH30 cells (S100A8 on top left and S100A9 
lower left) stained with CD33-fusion (APC, red). (C) S100A9 capture-
ELISA of lysates from untransfected (negative) or S100A9 transfected 
cells. Secondary antibody was either anti-S100A9 (positive control) 
or CD33-fusion. (D) Serial dilution of both AD293 and SJCRH30 cell 
lysates, either untransfected or transfected with vector or S100A9, onto 
a PVDF membrane and blotted with CD33-fusion. Coomassie blue 
staining serves as loading control. (E) S100A9 immunoprecipitation 
of SJCRH30 CD33/S100A9 cotransfected cell lysate blotted against 
CD33. (F) PBMC and BM-MNC from healthy (H) and MDS (M) sam-
ples immunoprecipitated with CD33-fusion and blotted for S100A9. (G) 
Immunofluorescence staining of rhS100A9-DDK incubated with either 
CD33-transfected (top) or vector-transfected (bottom) SJCRH30 cells at 
indicated time points. DAPI = nuclei, APC-DDK = rhS100A9. Treatment 
of SJCRH30-CD33 cells with rhS100A9 induced IL-10 (H) and TGF-β 
expression (I). Treatment of U937 cells (high CD33 expression myeloid 
cell line) with rhS100A9 also induced IL-10 (J) and TGF-β expression 
(K). S100A9 protein concentration in the plasma of MDS patients (n = 6) 
measured by ELISA (L). MDS-MDCS treated with 1 μg of rhS100A9 
were stained for CD33-FITC and anti-DDK-APC (M) and immunoprecip-
itated with anti-CD33 antibody followed by blotting with anti–SHP-1 (N). 
Original magnification, ×400 (B); ×200 (G); ×600 (M). (O) BM plasma 
from either healthy donors (n = 3) or MDS patients (n = 3) was used to 
assay SHP-1 recruitment. In all experiments, error bars represent the 
SEM of 3 separate experiments.
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yield a comparable impairment of hematopoietic integrity. These 
findings were supported by sequential analyses of peripheral 
blood counts in which mixed source transplant recipients had 
cytopenias that were intermediate in severity relative to those in 
mice receiving the S100A9Tg or WT donor cells (Figure 6, D–F). 
Interestingly, while mixed donor recipients had the same propor-
tion of HSPC after engraftment as Tg transplanted mice, their 
wbc counts were higher than those of mice transplanted with 
S100A9Tg HSPC and lower than the levels found in WT HSPC 
recipients. Similarly, onset of anemia was delayed in recipients of 
the mixed versus S100A9Tg donor cells, eventually matching the 
proportion of KLS HSPC in mixed versus transgenic mice at the 
end of the study (8 weeks, as shown in Figure 6C). These findings 
suggest that normal HSPC from WT mice are able to partially 
rescue hematopoiesis but, with time, it is suppressed by accumu-
lating MDSC derived from S100A9Tg donor cells.
To address whether S100A9 alone has direct effects on HSPC, we 
treated BM CD34+ (MDSC depleted, MDSC–) from MDS patient 
specimens with rhS100A9 for 24 and 48 hours and assessed 
apoptosis by flow cytometry. We observed a decrease in the num-
ber of CD34+ HSPC after treatment compared with controls 
accompanied by a corresponding increase in the apoptotic frac-
tion among surviving cells after 48 hours of exposure (Figure 6, 
G and H, and refs. 41–43). In order to corroborate these find-
ings, we cultured healthy BM-derived CD34+ cells (Lonza) with 
rhS100A9 and again observed a decrease in viable cells after treat-
ment (50.7% viability in control cells versus 24.7% in rhS100A9-
treated cells, Figure 6I). These findings suggest that S100A9 has 
a direct apoptotic effect in human HSPC.
Forced maturation of MDSC restores hematopoiesis. To confirm the 
effector role of MDSC and investigate the potential benefit of 
targeted suppression of MDSC, we treated S100A9Tg mice with 
all-trans-retinoic acid (ATRA). ATRA induces MDSC differentia-
tion into mature myeloid cells and neutralizes ROS production, 
thereby extinguishing MDSC through forced terminal differen-
tiation (44, 45). To this end, we examined whether ATRA would 
induce MDSC differentiation in S100A9Tg mice and improve 
hematopoiesis. S100A9Tg and WT mice were treated with ATRA 
(250 μg/200 μl) or vehicle control orally for 5 consecutive days. 
Two days after completion of the treatment, we found that ATRA 
reduced the total number of MDSC, while numbers in WT mice 
remained at basal levels (Figure 7A). Reductions in MDSC num-
bers in S100A9Tg mice were coupled to an increase in mature 
cells following ATRA treatment (Figure 7B). Treatment of prima-
ry MDS BM specimens with ATRA also reduced in vitro MDSC 
accumulation (data not shown). Importantly, BM progenitor 
cultures from ATRA-treated S100A9Tg mice showed signifi-
cantly improved BFU-E recovery compared with vehicle-treated 
controls (Figure 7C). Analysis of changes in peripheral blood 
counts showed that rbc, wbc, and platelet counts significantly 
increased compared with vehicle-treated controls (Figure 7D), 
indicating that terminal differentiation of MDSC can restore 
effective hematopoiesis.
Our investigations showed that MDSC employ CD33-associ-
ated ITIMs to inhibit their own cellular maturation (Figure 3, 
N and O). However, ITIM signals can be overridden by stimula-
tory immunoreceptor tyrosine–based activation motif–mediated 
(ITAM-mediated) signals (46, 47). Some CD33-related receptors, 
such as certain Siglecs, lack ITIMs and instead function as acti-
vating receptors. Mouse Siglec-H and human Siglec-14 have 
been shown to interact with DAP12 (26, 27, 48, 49), an ITAM-
containing adaptor that can promote myeloid cell maturation 
(Supplemental Figure 3) and inhibit TLR activation (50). We 
compared the DAP12 gene expression of purified MDS-MDSC 
(n = 5) to age-matched healthy donor MDSC (n = 5). DAP12 
mRNA was significantly lower in MDS-MDSC in all specimens 
tested (Figure 7E). We reasoned that overriding CD33-ITIM 
signaling via DAP12 would induce the differentiation of these 
immature myeloid cells and improve hematopoiesis. To test this 
hypothesis, we created a constitutively active form of DAP12, 
named P23, and transfected AD293 cells with GFP, WT-DAP12, 
or active-DAP12 P23 viral vectors. Our results show that P23 
binds Syk kinase and activates downstream signaling in trans-
duced AD293 cells without external stimulation (Figure 7F). 
Furthermore, P23 promotes primary human DC maturation as 
demonstrated by upregulation of CD80, CD83, and CCR7 anti-
gens (Supplemental Figure 4 and refs. 26, 27). Based on these 
findings, we examined whether P23 could induce the maturation 
of MDS-MDSC and thereby prevent or disrupt hematopoietic 
suppression. We analyzed expression of the human monocytic 
and granulocytic surface markers CD14 and CD15 after trans-
fection since this change, from CD14–/lowD15+ to CD14+CD15+ 
following active DAP12, indicates a shift to the monocyte/mac-
rophage lineage (51). We found that while WT-DAP12 transfec-
tion alone was sufficient to induce upregulation of CD14 and 
CD15, P23 transfection induced even greater expression of 
both maturation markers (Figure 7G). Moreover, P23 promoted 
the maturation of primary MDS-MDSC, as demonstrated by 
upregulation of CD80, CD83, and CCR7 maturation markers 
(Figure 7H). Finally, we tested whether DAP12-mediated MDSC 
maturation relieved suppression of erythropoiesis. We purified 
MDS-MDSC from 7 MDS patients and infected them with con-
trol, WT-DAP12, or P23 LV constructs. To asses the suppressive 
function of the mature MDS-MDSC on hematopoiesis, colony-
forming capacity was assessed after culture of infected cells with 
autologous, MDSC-depleted BM cells. P23-infected MDS-MDSC 
cocultures yielded significantly higher colony numbers than con-
trol viral vector or WT-DAP12–infected MDS-MDSC cocultures 
(Figure 7I). These findings indicate that DAP12 overrides CD33-
associated ITIM signaling to stimulate MDSC maturation and 
reverses the suppressive effects on HPC colony-forming capacity.
Figure 4
S100A9 signaling through CD33 in MDS BM is associated with MDSC 
activation and suppressive function. Healthy BM cells infected with 
adenovirus containing GFP or CD33 expression vectors assessed by 
qPCR for the expression of IL-10 (A), TGF-β (C), ARG2 (E), or NOS2 
(F), or by ELISA for IL-10 (B) and TGF-β (D). qPCR (G) and flow cytom-
etry of GFP expression (H) determined transfection efficiency. Healthy 
BM cells’ RAGE, TLR4, CD33, or their combination were blocked prior 
to culturing cells by themselves or with 1 μg of S100A9 for 48 hours 
to determine IL-10 gene and protein expression (qPCR in the top and 
ELISA on the bottom) (I) or TGF-β gene and protein expression (J). 
(K) Silencing S100A8 and S100A9 expression in primary MDS-BM 
cells using specific shRNA (demonstrated by Western blot) inhibits the 
expression of IL-10 (L) and TGF-β (M). *P < 0.01; **P < 0.001, versus 
cells treated with control shRNA. (N) Blocking S100A8 and S100A9 
expression by specific shRNA promotes colony formation in BM cells 
isolated from patients with MDS. *P < 0.05, versus cells treated with 
control shRNA. In all experiments, error bars represent the SEM of 
triplicate determination with 3 separate primary specimens.
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Figure 5
S100A9Tg mice have increased accumulation and activation of MDSC and display dysplastic features that recapitulate human MDS pathology. 
(A) Gr1+CD11b+ MDSC accumulation in BM-MNC isolated from S100A9Tg mice at 6, 18, or 24 weeks and S100A9KO or WT mice at both 6 and 
24 weeks. (B) Percentage of MDSC from BM, spleen, and PBMC of S100A9Tg mice at 6, 18, and 24 weeks of age by flow cytometry. Spleen cells 
from B were also assayed against the maturation markers F4/80+Gr1– (C) and I-Ad+ (D). (E) FACS-sorted Gr-1+CD11b+ cells (+MDSC) from the 
BM of mice described in A remixed back with autologous 1 × 105 MDSC-negative population (containing HSPC, –MDSC) at 1:1 ratio for 14 days 
before evaluating colony formation. An MDSC-depleted population was used as the control. (F) MDSC from WT, S100A9Tg, and S100A9KO mice 
were FACS sorted and incubated in a 96-well plate for 24 hours after which IL-10 and TGF-β production were measured by ELISA. Comparison of 
the hematopathological analysis of WT (G–J) and S100A9Tg mice (K–N) Original magnification, ×200 (G and K); ×600 (H and L); ×1000 (J, I, M, 
and N). Detailed descriptions is in Methods. MDS-BM primary specimens were tested for the location of S100A9 in CD33+ cells (O) and CD34+ 
cells (P). Flow figures are representative of triplicate experiments.
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Discussion
Inflammatory stimuli within the BM microenvironment are recog-
nized as important biological signals stimulating progenitor cell 
proliferation and apoptosis in MDS. A recent population-based 
study extended this further by demonstrating a strong linkage 
between chronic immune stimulation and MDS predisposition 
(4). Definitive evidence that niche intrinsic abnormalities per se 
can alone account for development of MDS in a cell-nonautono-
mous fashion are limited. Raaijmakers and colleagues showed that 
selective osteoprogenitor dysfunction caused by deletion of Dicer1 
in the mesenchymal component of the BM microenvironment was 
sufficient to perturb hematopoiesis and lead to development of 
myeloid dysplasia, followed by secondary emergence of myeloid-
restricted genetic abnormalities (52).
Our studies show that Lin–HLA-DR–CD33+ MDSC accumu-
late in the BM of MDS patients, derive from a population that is 
distinct from the neoplastic clone, and serve as cellular effectors 
that suppress hematopoiesis, promote T cell tolerance, and serve 
as a key source of myelosuppressive and inflammatory molecules 
such as IL-10, TGF-β, NO, and arginase. Using multiple biological 
and biochemical approaches, we show that S100A9 can serve as an 
endogenous native ligand for CD33/Siglec 3. Furthermore, forced 
expansion of MDSC by overexpression of S100A9 in transgenic 
mice initiates development of hematologic features that phenocopy 
human MDS, specifically progressive age-dependent ineffective and 
dysplastic hematopoiesis. These findings indicate that expansion of 
a single cellular constituent of the BM microenvironment is suffi-
cient to foster neoplastic change in heterologous myeloid progeni-
tors through niche-conducive oncogenesis. The time-dependent 
accumulation of MDSC in the transgenic mouse model parallels 
data from recent human studies showing that MDSC expand with 
age, accompanied by rising serum levels of inflammatory cytokines 
(e.g., TNF-α, IL-6, and IL-1β), providing evidence that such senes-
cence-dependent changes driving MDSC expansion may play an 
important role in the age-dependent predisposition to MDS (35). 
Importantly, the LIN–HLA-DR–CD33+ phenotype did not alone 
confer suppressor cell function, as evidenced by lack of LIN–HLA-
DR–CD33+ MDSC suppression from age-matched healthy donors 
or non-MDS cancer patients. Our studies demonstrate the necessity 
for activation of innate immune signaling and generation of proin-
flammatory molecules, such as S100A9, for the induction of MDS-
MDSC–mediated suppressor function. Furthermore, our finding 
that primary human MDS-MDSC lack molecular genetic abnor-
malities intrinsic to the malignant clone indicate that MDSC derive 
from nonneoplastic HSPC and that MDSC activation and expan-
sion likely precede emergence of genetically distinct MDS clones.
We show, for what we believe is the first time, that CD33, a Siglec 
receptor expressed by many immune cells including MDSC, is 
markedly overexpressed by MDS-MDSC and that this receptor 
controls the suppressive functions of MDS-MDSC through dis-
ruption of ITIM-mediated signaling. Additionally, our findings 
that rhS100A9 directly triggers apoptosis in human HPC indicate 
that this ligand exerts dual roles in the promotion of ineffective 
hematopoiesis that involve both cellular (MDSC) and humoral 
mechanisms (CD33, TLR4). Moreover, cellular response to CD33 
ligand engagement appears cell-type specific, i.e., triggering apop-
tosis in HPC versus activation and proliferation in MDSC. Com-
pensatory regeneration within the myeloid compartment may 
account for the increased proliferative index observed in MDS (41) 
and preferential myeloid skewing that occurs with age. Indeed, we 
found that myeloid mass significantly increased with age in the 
S100A9Tg mice, accompanied by a significant rise in the propor-
tion of cycling BM precursors (Supplemental Figure 1). We propose 
a model in which overexpression of CD33 impairs maturation sig-
nals from ITAM-associated receptors that is critical to expansion 
of immature MDSC (Supplemental Figure 3). Consistent with 
this, shRNA silencing of CD33 reduced myelosuppressive cytokine 
elaboration and, importantly, restored hematopoietic progenitor 
colony-forming capacity. Moreover, constitutively active DAP12 
signaling was sufficient to override CD33-ITIM inhibition and 
induce MDSC differentiation, which restored erythropoiesis upon 
active-DAP12 transfection into MDS-MDSC. DAP12 activation can 
inhibit TLR-mediated signaling pathways, which may also play a 
role in inflammation-mediated BM suppression (50, 53).
Table 1
CBC of S100A9Tg and WT mice
  6 weeks  18 weeks  24 weeks 
Test Units WT S100A9Tg WT S100A9Tg WT S100A9Tg
wbc 103/μl 5.4 ± 0.5 4.2 ± 1.5 6.0 ± 1.4 2.9 ± 0.2A 6.3 ± 0.8 3.0 ± 0.4A
LYM 103/μl 3.9 ± 0.5 2.6 ± 1.2 4.7 ± 1.1 2.4 ± 0.1A 4.8 ± 0.7 2.5 ± 0.3A
MONO 103/μl 0.4 ± 0.1 0.3 ± 0.2 0.4 ± 0.1 0.2 ± 0.1A 0.4 ± 0.1 0.2 ± 0.1A
GRAN 103/μl 1.1 ± 0.6 1.2 ± 1.2 0.9 ± 0.3 0.3 ± 0.2A 1.1 ± 0.4 0.3 ± 0.1B
HCT % 48.1 ± 3.2 42.4 ± 2.1 45.7 ± 0.7 35.5 ± 3.0B 45.4 ± 3.5 32.1 ± 2.7B
MCV fl 51.4 ± 1.6 49.8 ± 2.0 50.3 ± 0.5 50.0 ± 1.2 50.0 ± 1.3 50.0 ± 1.6
RDWa fl 35.0 ± 0.7 33.2 ± 2.2 34.0 ± 1.3 32.5 ± 1.7 33.3 ± 1.4 32.2 ± 1.5
RDW % 16.3 ± 0.7 15.9 ± 0.1 16.3 ± 0.5 15.5 ± 0.5 16.0 ± 0.5 15.4 ± 0.6
Hgb g/dl 14.2 ± 0.8 13.0 ± 0.7 13.9 ± 0.3 11.1 ± 0.7B 13.7 ± 0.6 10.3 ± 0.5B
MCHC g/dl 29.5 ± 1.1 30.6 ± 1.3 30.4 ± 0.4 31.5 ± 0.9 30.3 ± 1.0 32.3 ± 1.1
MCH pg 15.1 ± 0.3 15.2 ± 0.1 15.3 ± 0.1 15.8 ± 0.3 15.2 ± 0.2 16.2 ± 0.4
rbc 106/μl 9.4 ± 0.7 8.5 ± 0.4 9.1 ± 0.1 7.1 ± 0.6B 9.1 ± 0.3 6.4 ± 0.2C
PLT 103/μl 555.7 ± 96.6 412.0 ± 124.0 431.3 ± 33.9 95.7 ± 35.0C 437.0 ± 41.9 61.0 ± 23.5C
All data are mean ± SEM (n = 5 mice). Peripheral blood samples were prepared from both S100A9Tg and control (WT) mice at the ages of 6, 18, and  
24 weeks and analyzed on a Hema True Hematology Analyzer (Heska). AP < 0.05; BP < 0.01; CP < 0.001 vs. WT mice. LYM, lymphocytes; MONO, 
monocytes; GRAN, granulocytes; HCT, hematocrit; MCV, mean corpuscular volume; RDWa, rbc distribution with average; RDW, rbc distribution width; 
MCHC, mean corpuscular hemoglobin concentration; MCH, mean corpuscular hemoglobin; PLT, platelets.
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Mounting evidence implicates activation of innate immune 
signaling in the pathogenesis and biologic features of human 
MDS (7–9). In del(5q) MDS, allelic deletion of miRNA-145 and 
miRNA-146a results in derepression of the respective targets, 
TIRAP and TRAF6. Of particular importance, Starczynowski and 
colleagues showed that knockdown of these specific miRNAs or 
overexpression of TRAF6 in murine HSPC recapitulated hema-
tologic features of del(5q) MDS in a transplant model through 
both cell-autonomous and nonautonomous mechanisms involv-
ing IL-6 (10, 54). A recent study showed that IRAK1, a TLR4 
adaptor kinase, is overexpressed and hyperactivated in MDS and 
that IRAK1 inhibition impaired expansion of MDS HPC, while 
sparing normal CD34+ cells (55). Our studies show that the het-
erodimeric DAMP S100A8/S100A9, specifically released at BM 
inflammatory sites, is not only aberrantly expressed in MDS 
but serves as a native ligand for CD33 and a critical effector of 
Figure 6
Mix transplant of S100A9- and 
WT-enriched HSPC continues 
effects on hematopoiesis. (A) Pro-
portion of MDSC in lethally irradi-
ated mice (900 cGy) transplanted 
with enriched HSPC from WT, 
S100A9Tg, or a 1:1 mixture of the 
2 at 8 weeks (after engraftment). 
(B) GFP expression of MDSC from 
the experiments in A. (C) Percent-
age of KLS stem cells, defined as 
Lineage–cKit+Sca-1+, in lethally 
irradiated mice after transplant 
with WT, S100A9Tg, or 1:1 mix of 
enriched HSPC. Proportion and 
concentration of wbc (D), Hgb (E), 
and rbc (F) measured weekly by 
CBC after transplant. Error bars 
are the SEM of n = 5. (G) Per-
centage of CD34+ cells in MDSC-
depleted MDS-BM specimens 
treated with or without S100A9 for 
48 hours. (H) Same experiment as 
in G, assessing surface expres-
sion of annexin V and PI after 
treatment with S100A9. (I) Healthy 
human CD34 cells were treated 
as in H and cultured for 48 hours 
followed by annexin V/PI flow cyto-
metric analysis.
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was purified from the same patients who were previously confirmed to have 
del5q or del7q using a commercially available test (Abbott Laboratory).
Immunostaining. BM-MNC were purified from MDS patients, diluted to a 
concentration of 3 × 105 cells/ml, cytospinned onto microscope slides and 
fixed with methanol/acetone (3:1 ratio at –20°C for 30 minutes). Washes 
were done with Triton X-100 buffer for 5 minutes and 50 mM Tris buf-
fer (pH 7.4) for 10 minutes prior to blocking for nonspecific binding with 
serum. We stained the slides with the following primary antibodies: rab-
bit anti-CD33 antibody (1:100 dilution; Santa Cruz Biotechnology Inc.); 
mouse anti-granzyme B (1:100 dilution; Fitzgerald Industries); and mouse 
anti-human CD71 (1:100 dilution; BD Biosciences). This was followed by 
their respective secondary antibodies: Alexa Fluor 594 goat anti-rabbit IgG 
(Invitrogen); FITC goat anti-mouse (Sigma-Aldrich); and Alexa Fluor 350 
goat anti-mouse IgG (Molecular Probes). Rat anti-human glycophorin A was 
preconjugated to Alexa Fluor 647 using a kit from Molecular Probes before 
addition to the sample (1:50 dilution; AbD Serotec) followed by mounting 
the slides with aqueous medium (Molecular Probes). Immunofluorescence 
was detected using a Zeiss automated upright fluorescence microscope and 
images captured by a Nikon camera with the capture program AxioVision.
Immunostaining on S100A9 transfected SJCRH30 cells. Detailed methods 
have been published previously (25). Specifically, SJCRH30 cells that 
lack detectable expression levels of both CD33 and S100A9 were trans-
fected with either S100A9 or S100A8 (negative control) for 48–72 hours. 
After incubation with CD33-fusion for 30 minutes (2 μg/ml) they were 
stained with a secondary anti-human IgG1-APC before analysis by 
immunofluorescence microscopy. Similarly, SJCRH30 cells, stable-trans-
fected with CD33, were incubated with rhS100A9 tagged with DDK for 
various time points and stained by the same methodology before analysis.
Suppression assays. To determine whether MDSC are capable of mediat-
ing T cell suppression, MDSC were sorted from full BM of MDS patients 
by FACS. T cells were isolated by MACS using CD3 microbeads (Miltenyi 
Biotec) from autologous peripheral blood. 2 × 104 T cells were seeded in 
96-well round-bottom plates in triplicate in Iscove’s modified Dulbecco 
medium (IMDM; Invitrogen) supplemented with 10% human serum PAA 
(PAA Laboratories). Cultures were stimulated with 30 U/ml IL-2 (Chiron) 
and anti-CD3/anti-CD28–coated beads (Invitrogen) at a 1:2 ratio of T cells 
to beads. MDSC were admixed with T cell cultures at ratios of 1:2 and 1:4. 
After 3 days of coculture, supernatants were harvested to measure IFN-γ 
concentration by ELISA (Pierce Endogen). Subsequently, 0.5 μCi 3H-thymi-
dine (PerkinElmer) was added to each well, and after overnight incubation, 
3H-thymidine incorporation was measured using a 1205 Wallac Betaplate 
counter (PerkinElmer). To determine whether differences in proliferation 
and IFN-γ production were statistically significant, 1-way ANOVA with 
Bonferroni’s post-hoc test was used. P < 0.05 was considered significant.
Colony-forming assay. Cells isolated from either human BM or from 
S100A9Tg, S100A9KO, or WT tibias and femurs were seeded into complete 
methylcellulose medium (MethoCult complete medium with necessary 
cytokines and growth factors; StemCell Technologies) following the manu-
facturer’s instructions. After incubation, colonies of BFU-E and GM-CFU 
were counted using an inverted light microscope.
Real-time quantitative PCR. RNA was isolated by Trizol isolation 
(Invitrogen) followed by iScript cDNA synthesis (Bio-Rad) and amplifica-
tion using iQ SYBR Green Supermix (Bio-Rad). The relative level of gene 
expression for each experimental sample was calculated by the ΔΔCt meth-
od, where untreated cells were the experimental control and the house-
keeping gene GAPDH was the internal control. Error bars represent the 
SEM of 3 separate experiments.
Preparation of the CD33/Siglec 3 chimeric fusion protein. Recombinant sol-
uble fusion of CD33/Siglec 3 ectodomain was constructed as described 
previously (59–61). Specifically, cDNA fragments encoding CD33/Siglec 3 
MDSC expansion and HPC apoptosis. This finding provides evi-
dence that S100 proteins contribute directly to MDS pathogen-
esis through microenvironment-directed, cell-nonautonomous 
mechanisms involving MDSC (18, 56). Moreover, TLR activation 
suppresses osteoblast differentiation, while instructing myeloid 
commitment in HSPC (12, 13). Prolonged activation of innate 
immune signaling with age, therefore, may disrupt the BM end-
osteal niche-supporting maintenance of HSPC quiescence and 
favor translocation of myeloid progenitors to an angiogenic niche 
characteristic of MDS (57). Our findings of a skewed distribu-
tion of cycling precursors along the endosteal region in S100A9Tg 
mice, coupled with the myeloid lineage expansion with age sup-
port this notion. More importantly, the competitive transplant 
experiments showed that admixture of S100A9Tg with WT donor 
HSPC delays suppression of hematopoiesis.
Our findings support a model for MDS pathogenesis in which 
sustained activation of innate immune signaling in the BM micro-
environment creates a permissive inflammatory milieu that is 
sufficient for development of myelodysplasia. Cell-autonomous 
neoplastic hematopoietic progenitors may emerge following acqui-
sition of secondary genetic abnormalities in the myeloid compart-
ment. S100A9Tg mice simulate human MDS and can serve as an 
in vivo model for studying MDS pathogenesis and development of 
novel therapeutics. Nevertheless, our data suggest that therapeutic 
interventions that promote MDSC maturation may have remitting 
potential when applied early in the disease course.
Methods
MDS patients. The majority of patients with MDS were low risk unless 
otherwise specified. All patients were confirmed by central review and 
classified in accordance with either the World Health Organization cri-
teria or the International Prognostic Scoring System (IPSS). Patients were 
recruited from the Malignant Hematology clinic at the H. Lee Moffitt 
Cancer Center & Research Institute and the Radboud University Nijme-
gen Medical Centre, Department of Hematology. BM-MNC were isolated 
from heparinized BM aspirates by Ficoll-Hypaque gradient centrifugation, 
as previously described (58). MDSC were defined and purified by FACS 
of CD33+ cells lacking expression of lineage (Lin–) markers (CD3, CD14, 
CD16, CD19, CD20, CD56) and HLA-DR.
Mice. WT FVB/NJ mice were purchased from Jackson Laboratories, and 
S100A9KO mice and S100A9Tg mice were generated and used as previ-
ously described (37, 38). S100A9Tg mice were generated from FVB/NJ 
homozygous mice and bred for more than 15 generations. Each experi-
ment group included 5 to 10 mice. For the competitive adoptive transplant 
experiment, 18-week-old FVB/NJ WT female mice were irradiated once in 
a rotating gamma irradiator for a total dose of 900 cGy. Concurrently, BM 
cells were isolated from the tibias and femurs of age-matched male WT or 
S100A9Tg mice from which HSPC were then enriched by magnetic cell 
sorting (MACS; Miltenyi Biotech) following the manufacturer’s proto-
col. Six hours after irradiation, 1 × 107 enriched HSPC were given by tail 
vein injection into recipient mice. Mice were then monitored every other 
day with weight measurements under a sterile hood. Peripheral blood for 
CBC was collected from the anteroorbital vein by Vivarium staff at the 
center weekly. By 8 weeks (after which the WT recipients were engrafted, 
wbc > 3 × 103 cells/ml of blood), mice were euthanized by CO2 aspiration, 
at which point peripheral blood was collected by heart puncture followed 
by dissection of tibias and femurs (as before) and spleen for assessment.
FISH. FISH was done at the Cytogenetics Laboratory of Moffitt Cancer 
Center, and detailed methods have been previously described (58). Target 
DNA from MDSC-positive (MDS-MDSC) cells and MDSC-negative cells 
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Preparation of adenoviral vector expressing CD33. CD33 plasmid (GeneCopeia) 
was subcloned into a pShuttle-IRES-hrGFP-1 vector (containing the CMV 
promoter and hrGFP). The PmeI-digested shuttle vectors were then cotrans-
formed into electrocompetent BJ5183 bacteria with pAdEasy-1 (containing 
the viral backbone) and selected on Kanamycin LB plates. The plasmid in 
the bacteria was amplified and purified using a plasmid maxiprep system 
(QIAGEN). The complete adenoviral vector was linearized by PacI digestion 
and then transfected into AD293 cells using Lipofectamine (Invitrogen). All 
recombinant adenoviruses were amplified in AD293 cells. Viral stocks were 
obtained by amplification of the AD293 cells followed by standard 2-step 
CsCl gradient ultracentrifugation, dialysis, and storage in a glycerol stock 
(10% vol/vol) at –80°C. The titer of each viral stock was routinely tested to 
be 1011–1012 PFU by plaque-forming assay using AD293 cells.
Preparation of shRNA LVs. SureSilencing shRNA Plasmid for Human 
S100A8, S100A9, and CD33 and negative control (nontarget) were pur-
chased from SABiosciences. 293T cells were transfected using Attactene 
reagent (SABiosciences) according to the manufacturer’s instructions. 
Virus containing medium was collected 24–48 hours later. Plasmids, 
pcDNA3 WT DAP12 and P23-DAP12 were cut with HindIII and XhoI 
(Promega), and DNA Polymerase I Large (KlenowI) (New England Bio-
labs Inc.) was used to fill in recessed 3′ ends of DNA fragments. pWPI, 
which contains a GFP expression cassette (Addgene Organization), was 
digested using PMEI (New England Biolabs Inc.). After cutting DNA and 
vector, pWPI was purified by Strata Prep PCR purification kit (QIAGEN), 
DNAs were ligated (Takara DNA Ligation Kit; Fisher) into vector pWPI, 
and STBL2 competent cells were transformed (Invitrogen). 293T cells were 
transfected with pWPI lentivirus vector, the packaging plasmid psPAX2, 
and the envelope plasmid pMD2.G (Addgene Organization) using Lipo-
fectamine 2000 (Invitrogen) at a ratio of 4:3:1 according to standard pro-
tocols. Four days after the first infection, transduced cells were isolated by 
FACS sorting GFP+ cells with greater than 99% purity.
Infection of MDSC from MDS patients. MDSC isolated from MDS patients 
were infected 3 times using virus-containing infection medium at 24-hour 
intervals in the presence of 8 μg/ml polybrene. For each infection, cells 
were plated in 12-well dishes at 1 × 106 cells/well. Four days after the first 
infection, cells were harvested and used for qPCR, Western blot analysis, 
flow cytometry, or colony formation assays.
Flow cytometry. BM-MNC were stained with appropriate specific conju-
gated antibodies in PBS with 2% BSA buffer. For MDSC sorting, FITC anti-
CD33 and FITC anti-HLA-DR were used as positive controls and isotype 
IgG was used for negative control and to detect nonspecific staining. Sort-
ing was performed on a FACSAria cell sorter by Core facility personnel. For 
antigenic determination, cells were washed in PBS and then stained with 
PE-conjugated mAbs specific to CD40, CD80, CD83, CD86, CCR7, CD11c, 
CD14, HLA-DR, TLR2, or TLR4 and relevant isotype controls (eBioscience) 
for 30 minutes in the dark, on ice. Live cells were gated based on negative 
staining for 7-AAD. Samples were acquired on a FACSCalibur flow cytom-
eter, and the analysis was performed using FlowJo 6.3.4 software.
Arginase activity. Arginase activity was measured in cell lysates as previ-
ously described (62). In brief, cells were lysed for 30 minutes with 100 μl 
of 0.1% Triton X-100. Subsequently, 100 μl of 25 mM Tris-HCl and 10 μl 
of 10 mM MnCl2 were added, and the enzyme was activated by heating for 
10 minutes at 56°C. Arginine hydrolysis was conducted by incubating the 
lysate with 100 μl of 0.5 M l-arginine (pH 9.7) at 37°C for 120 minutes. The 
reaction was stopped with 900 μl of H2SO4 (96%)/H3PO4 (85%)/H2O (1/3/7, 
v/v/v). Urea concentration was measured at 540 nm after addition of 40 μl 
of α-isonitrosopropiophenone, followed by heating at 95°C for 30 minutes.
NO production. Equal volumes of culture supernatants (100 μl) were 
mixed with Greiss reagent solution (1% sulfanilamide in 5% phosphoric 
acid and 0.1% N-1-naphthylethylenediamine dihydrochloride) in double-
ectodomain were amplified by PCR and inserted into a vector that encodes 
the human Fcγ followed by a C terminal recognition site for E. coli biotin 
ligase. This vector has been engineered to facilitate the fusion of gene seg-
ments encoding extracellular Ig-type domains to the Fc region of human 
IgG1. The recombinant proteins were expressed in 293T cells after transfec-
tion, using Lipofectamine (Invitrogen), with 3 successive harvests of 25 ml 
OPTI-MEM I serum-free medium. The harvests were pooled, centrifuged at 
500 g for 10 minutes to remove debris, and stored at 4°C in 0.02% sodium 
azide. Concentrations of CD33-fusions in culture supernatants were deter-
mined by Bradford assay (Bio-Rad).
Mass spectrometry. Following in-gel tryptic digestion, peptides were 
extracted and concentrated under vacuum centrifugation. A nanoflow 
liquid chromatograph (Easy-nLC; Proxeon) coupled to an electrospray ion 
trap mass spectrometer (LTQ; Thermo) was used for tandem mass spec-
trometry peptide sequencing experiments. The sample was first loaded 
onto a trap column (BioSphere C18 reversed phase resin, 5 μm, 120 Å, 
100 μm ID; NanoSeparations) and washed for 3 minutes at 8 ml/min. The 
trapped peptides were eluted onto the analytical column (BioSphere C18 
reversed-phase resin, 150 mm, 5 μm, 120 Å, 100 μm ID; NanoSeparations). 
Peptides were eluted in a 60-minute gradient from 5% B to 45% B (solvent 
A: 2% acetonitrile + 0.1% formic acid; solvent B: 90% acetonitrile + 0.1% 
formic acid) with a flow rate of 300 nl/min. Five tandem mass spectra were 
collected in a data-dependent manner following each survey scan. Sequenc-
es were assigned using Mascot (www.matrixscience.com) searches against 
human IPI entries. Carbamidomethylation of cysteine, methionine oxida-
tion, and deamidation of asparagine and glutamine were selected as vari-
able modifications, and as many as 2 missed tryptic cleavages were allowed. 
Precursor mass tolerance was set to 2.5 and fragment ion tolerance to 0.8. 
Results from Mascot were compiled in Scaffold, which was used for manu-
al inspection of peptide assignments and protein identification.
Identification of specific binding of S100A9 to CD33/Siglec 3. Ninety-six–well 
flat-bottom ELISA plates were coated overnight with 1 μg/ml of monoclo-
nal anti-S100A9, as per the manufacturer’s suggestions. After washing with 
1× PBS-T, 50 μl of lysates from untransfected cells (negative) or S100A9 
transfected cells was added to the wells. Secondary antibody was either a 
S100A9 polyclonal antibody (positive control) or CD33-fusion as indicated 
followed by ELISA HRP reaction analysis at 440 nm.
Figure 7
Targeting MDSC activation and signaling can improve suppressive BM 
microenvironment. ATRA decreases MDSC in the BM of S100A9Tg 
mice (A) and promotes the expression of myeloid maturation mark-
ers (B). (C) BFU colony formation of WT and S100A9Tg mouse BM 
cells treated with ATRA. All of the cultures were duplicates. *P < 0.05, 
between ATRA-treated and vehicle-treated S100A9Tg mice and (D) the 
number of rbc, wbc, and platelets from CBC analysis of ATRA-treated 
and untreated mice. *P < 0.05, between ATRA-treated and vehicle-
treated S100A9Tg mice. (E) Relative expression levels of DAP12 
from isolated MDSC from either healthy or MDS specimens by qPCR 
(n = 5). (F) AD293 cells were transfected with either vector, WT-DAP12, 
dominant negative (DN) DAP12, or active DAP12 (P23) for 48 hours 
and analyzed by Western blot for the expression of phosphorylated 
or total Syk and ERK. This is representative of 3 independent experi-
ments. MDSC were isolated from the BM of MDS patients and infected 
with adenoviral vector containing either WT or active DAP12 (P23) 
for 48 or 72 hours. The surface expression of CD14 or CD15 (G) or 
the maturation markers CD80, CCR7, and CD11c (H) was then ana-
lyzed by flow cytometry. (I) MDSC were purified from BM-MNC of MDS 
patients by FACS sorting, and cells were infected with LV-WT DAP12 
or LV-P23. Colony formation assays were performed in methylcellulose 
for 14 days. Results are shown as mean ± SEM of 7 patients. *P < 0.01; 
**P < 0.001, versus cells infected with LV-WT.
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Mixed myeloid and erythroid precursors are normally distributed with 
estimated M/E ratio of 2:1 (H&E, ×600). Wright-Giemsa–stained BM aspi-
rate exhibited full maturation in all 3 lineages without dysplastic features 
(Wright-Giemsa, ×1000; Figure 5I). Inlet showed a normal lobated mega-
karyocyte. Touch imprint of mouse spleen displayed predominance of small 
and mature-appearing lymphocytes intermingled with occasional erythro-
poietic precursors (Wright-Giemsa, ×1000; Figure 5J). S100A9Tg mice BM 
core biopsy revealed hypercellularity, approximately 95% with increased 
megakaryocytes, especially in small forms (H&E, ×200; Figure 5K). 
High-power magnification highlighted dysplastic megakaryocytes with 
single, hypolobated, or disjointed nuclei and markedly increased in number 
(H&E, ×600, insert; Figure 5L). Inlet included 2 markedly dysplastic micro-
megakaryocytes with hypolobation. BM aspirates exhibited mildly increased 
blasts admixed with myeloid and erythroid precursors (Figure 5M). 
The latter demonstrated slightly irregular nuclear contour and minimal 
megaloblastoid changes (Wright-Giemsa, ×1000). Inlet (insert) contained 
2 blasts showing delicate or fine chromatin, prominent nucleoli, a high 
N/C ratio, and scant basophilic cytoplasm. Touch preparation of trans-
genic mouse spleen showed increased erythroid precursors,; some of them 
displaying enlarged size with abnormal nuclearity and occasional nuclear 
bridge (Wright-Giemsa, ×1000; Figure 5N).
Statistics. All data are presented as mean ± SEM. Statistical calculations 
were performed with Microsoft Excel or GraphPad Prism analysis tools. 
Differences between individual groups were analyzed by paired t test. 
P < 0.05 was considered statistically significant.
Study approval. All mouse experiments were approved by the Institutional 
Animal Care and Use Committee at the University of South Florida.
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distilled water and incubated for 10 minutes at room temperature. Absor-
bance of the mixture was measured at 550 nm using a microplate reader 
(Bio-Rad). Nitrite concentrations were determined by comparing the 
absorbance values for the test samples to a standard curve generated by 
serial dilution of 0.25 mM sodium nitrite.
Western blot analysis. Cell lysates were prepared by resuspending cell pel-
lets in 1% NP-40, 10 mM Tris, 140 mM NaCl, 0.1 mM PMSF, 10 mM iodo-
acetamide, 50 mM NaF, 1 mM EDTA, 0.4 mM sodium orthovanadate, 
10 μg/ml leupeptin, 10 μg/ml pepstatin, and 10 μg/ml aprotinin and 
lysing on ice for 30 minutes. Cell lysates were centrifuged at 12,000 g for 
15 minutes to remove nuclei and cell debris. The protein concentration 
of the soluble extracts was determined by using the Bio-Rad (Bradford) 
protein assay. 50 μg of protein (per lane) was separated on a 10% SDS-
polyacrylamide gel by electrophoresis, then transferred to a PVDF mem-
brane. Membranes were probed for indicated antibody: anti-S100A8, 
anti-S100A9, or anti-S100A8/A9 (Santa Cruz Biotechnology Inc.); anti-
phospho ERK, anti-total ERK, anti-phospho Syk, and anti-total Syk (Cell 
Signaling). Proteins were detected with the enhanced chemiluminescence 
detection system (ECL; Amersham).
In vitro dot blotting analysis of direct binding of S100A9 to CD33. Lysate from 
S100A9 untransfected, empty vector, and S100A9 transfect SJCRH30 or 
AD293 cells was serially diluted (as indicated in Figure 3) with the first lysate, 
starting at 50 μg, followed by loading onto a nitrocellulose membrane and 
blocking overnight at 4°C in 5% milk. Following incubation with CD33-
fusion for 2 hours at room temperature, and staining with an anti-human 
IgG HRP-conjugated secondary, the membrane was washed and used for 
radiograph analysis to demonstrated specific S100A9 binding to CD33. The 
membrane was afterwards used for Coomassie blue staining to show the rel-
ative equal loading of proteins on each dot in the nitrocellulose membrane.
CBC. CBC was performed by animal core laboratory pathological per-
sonnel in the Vivarium at the Moffitt Cancer Center. The mouse blood 
parameters were determined as described in Supplemental Table 1 with a 
Heska Hematrue Hematology Analyzer.
Pathological examination of spleen and BM biopsy from WT and S100A9Tg mice. 
BM cells were obtained from bilateral tibiae and femura from 6-month-old 
S100A9Tg and WT control mice as previously described (63). Touch prints 
of murine splenocytes were prepared as described elsewhere (64). BM aspi-
rates and touch imprints were stained using Wright-Giemsa stain. Sections 
of BM and spleen were fixed in 10% phosphate-buffered neutral formalin, 
decalcified (only applied to BM), and embedded in paraffin by routine pro-
cedures. Sections were cut at 4 μm and stained with H&E and PAS. The 
presence of myelodysplastic features characteristic of MDS was evaluated 
by an experienced hematopathologist. Comparisons of the hematopatho-
logical analysis of WT (Figure 5, G–J) and S100A9Tg (Figure 5, K–N) were 
performed at Moffitt’s hematopathology clinical research laboratories. BM 
core biopsy showed 50% cellularity with maturing trilineage hematopoiesis 
(H&E, ×200). Figure 5H shows a high-power view of the BM biopsy that 
demonstrates normal-appearing megakaryocytes with normal lobation. 
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